Sutro Biopharma Inc (STRO) Gets a Buy Rating from Cowen & Co.

By Jason Carr

Cowen & Co. analyst Boris Peaker maintained a Buy rating on Sutro Biopharma Inc (STROResearch Report) yesterday. The company’s shares closed yesterday at $10.15.

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 3.3% and a 41.8% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sutro Biopharma Inc with a $20 average price target, implying a 97.0% upside from current levels. In a report issued on May 7, H.C. Wainwright also maintained a Buy rating on the stock with a $18 price target.

See today’s analyst top recommended stocks >>

Based on Sutro Biopharma Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $1.49 million. In comparison, last year the company had a GAAP net loss of $1.42 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. The company was founded by James R. Swartz and Sutanto Widjaja in June 2003 and is headquartered in South San Francisco, CA.